Driving Shareholder Returns
30
30
Estimated GAAP Net Loss Attributable to Chemours to Estimated Adjusted Net Income,
Adjusted EBITDA and Adjusted EPS Reconciliation (*) (Unaudited)
(In millions except per share amounts)
(Estimated)
Year Ending December 31, 2023
Low
High
Net loss attributable to Chemours
Litigation-related charges
Gain on sales of assets and businesses
Restructuring, transaction, and other costs, net (1)
Adjusted Net Income
Interest expense, net
Depreciation and amortization
$
(201) $
(166)
675
675
(106)
(106)
52
52
420
455
215
215
300
300
All remaining provision for income taxes
90
105
Adjusted EBITDA
$
1,025
$
1,075
Weighted-average number of common shares outstanding - basic (2)
Dilutive effect of the Company's employee compensation plans (3)
Weighted-average number of common shares outstanding - diluted
148.8
2.9
151.7
148.8
2.9
151.7
Basic loss per share of common stock
Diluted loss per share of common stock (4)
Adjusted basic earnings per share of common stock
Adjusted diluted earnings per share of common stock (4)
$
(1.35)
$
(1.12)
(1.35)
(1.12)
2.82
3.06
2.77
3.00
(1) Restructuring, transaction, and other costs, net includes the net provision for (benefit from) income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete
income tax impacts; qualified spend recovery; shutdown of our Kuan Yin Taiwan manufacturing site and abandonment of ERP software implementation. Qualified spend recovery represents costs and expenses
that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU which is discussed in further detail in "Note 17 -
Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements.
(2) The Company's estimates for the weighted-average number of common shares outstanding - basic reflect results for the nine months ended September 30, 2023, which are carried forward for the projection
period.
(3) The Company's estimates for the dilutive effect of the Company's employee compensation plans reflect the dilutive effect for the nine months ended September 30, 2023, which is carried forward for the
projection period.
(4) Diluted earnings per share is calculated using net income available to common shareholders divided by diluted weighted-average common shares outstanding during each period, which includes unvested
restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-
dilutive effect.
* These estimates reflect the Company's visibility and expectations as of October 27, 2023, based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results
could differ materially from those estimates. The Company's estimates described herein are as of October 27, 2023, and are not updated or reaffirmed pursuant to this presentation.
Chemours™View entire presentation